INtRON Biotechnology (Korea) Today
| 048530 Stock | KRW 4,155 140.00 3.26% |
PerformanceVery Weak
| Odds Of DistressLow
|
INtRON Biotechnology is trading at 4155.00 as of the 26th of February 2025, a 3.26 percent decrease since the beginning of the trading day. The stock's open price was 4295.0. INtRON Biotechnology has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 4th of November 2023 and ending today, the 26th of February 2025. Click here to learn more.
iNtRON Biotechnology, Inc., a biotechnology company, develops bacterial bio-drugs for the treatment of infectious diseases. In addition, the company develops drugs targeting functional moieties, including axakacin, pterostilbene, methylated flavonoid, etc. The company has 29.88 M outstanding shares. More on iNtRON Biotechnology
Moving against INtRON Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
INtRON Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. INtRON Biotechnology's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding INtRON Biotechnology or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Thematic Ideas | (View all Themes) |
| Business Concentration | Biotech, Computers, Health Care, Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Computing (View all Sectors) |
iNtRON Biotechnology (048530) is traded on KOSDAQ in Korea and employs 93 people. The company currently falls under 'Mega-Cap' category with a current market capitalization of 265.62 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate INtRON Biotechnology's market, we take the total number of its shares issued and multiply it by INtRON Biotechnology's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. iNtRON Biotechnology operates under Biotechnology sector and is part of Health Care industry. The entity has 29.88 M outstanding shares.
iNtRON Biotechnology has accumulated about 75.17 B in cash with 16.47 B of positive cash flow from operations.
Check INtRON Biotechnology Probability Of Bankruptcy
Ownership AllocationiNtRON Biotechnology has a total of 29.88 Million outstanding shares. INtRON Biotechnology retains 15.72 (percent) of its outstanding shares held by insiders and 8.1 (percent) owned by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check INtRON Ownership Details
iNtRON Biotechnology Risk Profiles
Although INtRON Biotechnology's alpha and beta are two of the key measurements used to evaluate INtRON Biotechnology's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.3 | |||
| Standard Deviation | 3.84 | |||
| Variance | 14.71 | |||
| Risk Adjusted Performance | (0.05) |
INtRON Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in INtRON Biotechnology without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Diagnostics Now
Portfolio DiagnosticsUse generated alerts and portfolio events aggregator to diagnose current holdings |
| All Next | Launch Module |
INtRON Biotechnology Corporate Management
Elected by the shareholders, the INtRON Biotechnology's board of directors comprises two types of representatives: INtRON Biotechnology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of INtRON. The board's role is to monitor INtRON Biotechnology's management team and ensure that shareholders' interests are well served. INtRON Biotechnology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, INtRON Biotechnology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| SangHyun Kang | CTO Department | Profile | |
| Kyung Yoon | Chief Management | Profile | |
| SeongJun Yoon | Chief Pres | Profile | |
| JaeKoo Seol | MD Department | Profile | |
| Soo Jun | Director RD | Profile |
Other Information on Investing in INtRON Stock
INtRON Biotechnology financial ratios help investors to determine whether INtRON Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in INtRON with respect to the benefits of owning INtRON Biotechnology security.